Full history for every metric is available with a Kvantra account
Key financial summary
Financials in HUF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HUF bn | 567 | 631 | 803 | 805 | 858 | 923 | 917 | 889 |
| Operating profit | HUF bn | 322 | 325 | ||||||
| Net profit | HUF bn | 105 | 140 | 169 | 159 | 239 | 231 | 214 | 255 |
| EPS reported | HUF | 1,264 | 1,175 | ||||||
| Operating cashflow per share | HUF | 1,590 | 1,653 | ||||||
| Capex per share | HUF | 231.5 | 222.7 | ||||||
| FCF per share | HUF | 1,358 | 1,430 | ||||||
| Free cash flow | HUF bn | 248 | 274 | ||||||
| Net debt | HUF bn | -241 | -284 | ||||||
| Book value equity | HUF bn | 1,390 | 1,359 | ||||||
| Book value per share | HUF | 7,604 | 7,425 | ||||||
| Number of shares | m | 182.8 | 183.08 | ||||||
| DPS (TTM paid) | HUF | 655.0 | 655.0 |
Financial summary
Financials in HUF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 8.08 | 10.70 | ||||||
| P/B LTM | x | 1.33 | 1.69 | ||||||
| P/S LTM | x | 2.01 | 2.51 | ||||||
| P/FCF LTM | x | 7.47 | 8.39 | ||||||
| EV/EBITDA LTM | x | 4.72 | 5.32 | ||||||
| EV/Sales LTM | x | 1.82 | 2.20 | ||||||
| Earnings Yield LTM | % | 12.38% | 9.35% | ||||||
| FCF Yield | % | 13.38% | 11.91% | ||||||
| Quality | |||||||||
| ROE | % | 16.61% | 16.73% | ||||||
| ROIC | % | 17.08% | 16.00% | ||||||
| Operating margin | % | 34.85% | 33.69% | ||||||
| Gross margin | % | 68.99% | 67.55% | ||||||
| FCF/Sales | % | 26.88% | 28.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -3.31% | -2.65% | ||||||
| Sales Growth YoY | % | +7.68% | +1.52% | ||||||
| Net Income Growth YoY | % | -3.47% | -3.03% | ||||||
| FCF Growth | % | +15.12% | +22.79% | ||||||
| Operating Profit Growth | % | +23.21% | +18.01% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 4.99% | 5.22% | ||||||
| Dividend Growth | % | +27.69% | +27.69% | ||||||
| Payout Ratio | % | 40.05% | 40.87% | ||||||
| FCF/Debt | x | 7.08 | 14.25 | ||||||
| Net Debt/EBITDA | x | -0.49 | -0.69 | ||||||
| EBIT/Net interest | x | 4.10 | 5.81 | ||||||
| Net debt/market cap | % | -13.01% | -12.35% | ||||||
| Net debt/Equity | x | -0.17 | -0.21 | ||||||
| Gross debt/equity | x | 0.03 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free